Abstract
Purpose:
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.
Methods:
PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks.
Results:
Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic.
Conclusion:
PZA at the dose and schedule employed has insignificant activity in this population.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acridines / administration & dosage*
-
Acridines / adverse effects
-
Acridines / therapeutic use
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / pathology
-
Female
-
Humans
-
Middle Aged
-
Pyrazoles / administration & dosage*
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Treatment Outcome
-
Uterine Cervical Neoplasms / drug therapy*
-
Uterine Cervical Neoplasms / pathology
Substances
-
Acridines
-
Antineoplastic Agents
-
Pyrazoles
-
NSC 366140